rem0046127

REM0046127 is a first-generation, orally administered small molecule developed by reMYND for the treatment of Alzheimer's disease. Its mechanism centers on modulating Orai calcium (Ca2+) channel activity to normalize neuronal Ca2+ homeostasis in Alzheimer’s-diseased neurons, aiming to restore impaired synaptic function and neuronal network activity. The drug also acts as an inhibitor of the ORAI1 protein and has been described as a tau deposition inhibitor and neuroprotectant. Preclinical studies suggest it restores septin filament integrity in neurons, which regulates calcium homeostasis; this action is believed to mitigate amyloid-beta plaques and tau tangles, conferring both symptomatic improvement (e.g., memory retrieval) and potential disease-modifying effects. Clinical development reached Phase 2a but was terminated due to off-target liver toxicity concerns[1][3][6][9].

Other names

ReS19-T compoundReS-19-T compoundReS 19-T compound